Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification

1 hour ago 2

MarketBeat

Sat, May 16, 2026 astatine 11:06 AM CDT 7 min read

Key Points

Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s caller U.S. concern reset reflected a operation of customer-specific stock loss, softer marketplace trends and inventory-related factors, portion emphasizing that the diabetes instrumentality shaper is continuing a broader diversification strategy intended to marque the concern little babelike connected its halfway insulin injection franchise.

Speaking astatine a Bank of America event, Kurdikar described the company’s astir caller 4th — Embecta’s fiscal 2nd 4th and calendar archetypal 4th — arsenic “unquestionably a challenging quarter.” He said the U.S. business, which represents astir fractional of Embecta’s planetary business, had been unchangeable for years pursuing the company’s spinout, adjacent done COVID-related disruptions and inflationary pressures.

→ McDonald's Is the Cheapest It’s Been successful Years—Does That Make It a Buy?

That changed successful the latest quarter, helium said, arsenic respective factors converged and contributed to a simplification successful fiscal 2026 guidance.

U.S. Reset Driven by Share Loss, Market Softness and Inventory

Kurdikar said Embecta mislaid stock with 1 ample U.S. retailer, though its products stay disposable done that customer. He said the institution moved from the No. 1 presumption to the No. 2 presumption astatine that retailer.

→ How Berkshire’s New York Times Bet Looks Today

“In this peculiar case, I would accidental the azygous largest origin was price,” Kurdikar said, adding that the contented was not merchandise prime and that Embecta does not judge the broader competitory scenery has changed materially.

Read Entire Article